Definity Patent Expiration

Definity is a drug owned by Lantheus Medical Imaging Inc. It is protected by 14 US drug patents filed from 2013 to 2024. Out of these, 8 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be May 04, 2037. Details of Definity's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10588988 Methods and devices for preparation of ultrasound contrast agents
May, 2037

(12 years from now)

Active
US11529431 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US9789210 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US10583208 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US11857646 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US11925695 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US11266750 Methods for making ultrasound contrast agents
Mar, 2037

(12 years from now)

Active
US10583207 Lipid-encapsulated gas microsphere compositions and related methods
Dec, 2035

(11 years from now)

Active
US8658205 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jun, 2019

(5 years ago)

Expired
US8685441 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jan, 2019

(5 years ago)

Expired
US9545457 Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
Jan, 2019

(5 years ago)

Expired
US6033645 Methods for diagnostic imaging by regulating the administration rate of a contrast agent
Jun, 2016

(8 years ago)

Expired
US5527521 Low density microspheres and suspensions and their use as contrast agents for computed tomography and in other applications
Feb, 2015

(9 years ago)

Expired
US5585112 Method of preparing gas and gaseous precursor-filled microspheres
Dec, 2013

(10 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Definity's patents.

Given below is the list of recent legal activities going on the following patents of Definity.

Activity Date Patent Number
Patent litigations
Recordation of Patent eGrant 12 Mar, 2024 US11925695
Patent eGrant Notification 12 Mar, 2024 US11925695
Patent Issue Date Used in PTA Calculation 12 Mar, 2024 US11925695
Recordation of Patent Grant Mailed 12 Mar, 2024 US11925695
Email Notification 12 Mar, 2024 US11925695
Mail Patent eGrant Notification 12 Mar, 2024 US11925695
Email Notification 22 Feb, 2024 US11925695
Issue Notification Mailed 21 Feb, 2024 US11925695
Application Is Considered Ready for Issue 08 Feb, 2024 US11925695
Email Notification 08 Feb, 2024 US11925695

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Definity is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Definity's family patents as well as insights into ongoing legal events on those patents.

Definity's Family Patents

Definity has patent protection in a total of 17 countries. It's US patent count contributes only to 32.1% of its total global patent coverage. Click below to unlock the full patent family tree for Definity.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Definity's generic launch date based on the expiry of its last outstanding patent is estimated to be May 04, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Definity Generics:

There are no approved generic versions for Definity as of now.

Alternative Brands for Definity

Definity which is used for medical imaging using ultrasound technology., has several other brand drugs in the same treatment category and using the same active ingredient (Perflutren). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Lantheus Medcl
Definity Rt

(uses Perflutren)

used for diagnostic ultrasound imaging.





About Definity

Definity is a drug owned by Lantheus Medical Imaging Inc. It is used for medical imaging using ultrasound technology. Definity uses Perflutren as an active ingredient. Definity was launched by Lantheus Medcl in 2001.

Approval Date:

Definity was approved by FDA for market use on 31 July, 2001.

Active Ingredient:

Definity uses Perflutren as the active ingredient. Check out other Drugs and Companies using Perflutren ingredient

Treatment:

Definity is used for medical imaging using ultrasound technology.

Dosage:

Definity is available in injectable form for intravenous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
13.04MG/2ML (6.52MG/ML) INJECTABLE Prescription INTRAVENOUS